ICG-001 has been reported as an antagonist for Wnt/β-catenin/TCF-mediated transcription by which means it blocks the activation of downstream targets required for cell proliferation and tumor development by promoting apoptosis, reducing chemoresistance mediated by CSCs [54,55]. Here, HNF4A is linked to neoplasm.